Exploring the synergistic effects of cabozantinib and a programmed cell death protein 1 inhibitor in metastatic renal cell carcinoma with machine learning

Clinical evidence supports the combination of cabozantinib with an immune checkpoint inhibitor for the treatment of metastatic clear cell renal cell carcinoma (mccRCC) and suggests a synergistic antitumour activity of this combination. Nevertheless, the biological basis of this synergy is not fully...

Descripción completa

Detalles Bibliográficos
Autores principales: Durán, Ignacio, Castellano, Daniel, Puente, Javier, Martín-Couce, Lidia, Bello, Esther, Anido, Urbano, Mas, José Manuel, Costa, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794707/
https://www.ncbi.nlm.nih.gov/pubmed/35106125
http://dx.doi.org/10.18632/oncotarget.28183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794707/
https://www.ncbi.nlm.nih.gov/pubmed/35106125
http://dx.doi.org/10.18632/oncotarget.28183

Ejemplares similares